Neurocrine Biosciences, Inc.
ISIN US64125C1099
|WKN 900964
Overview
Description
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.
Healthcare Biopharmaceuticals System-Specific Biopharmaceuticals United States
Financials
Key metrics
| Market capitalisation, EUR | 10,200.46 m |
| EPS, EUR | 3.04 |
| P/B ratio | 4.11 |
| P/E ratio | 32.51 |
| Dividend yield | 0.00% |
Income statement (2024)
| Revenue, EUR | 2,177.42 m |
| Net income, EUR | 315.52 m |
| Profit margin | 14.49% |
What ETF is Neurocrine Biosciences, Inc. in?
There are 236 ETFs which contain Neurocrine Biosciences, Inc.. All of these ETFs are listed in the table below. The ETF with the largest weighting of Neurocrine Biosciences, Inc. is the First Trust NYSE Arca Biotechnology UCITS ETF Acc.
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.
Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.
Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.
